Curriculum Vitae

Name: Ursula Hanusch, M.D.
Born: on October 11th, 1969 in Vienna, Austria.
Citizenship: Austrian

School Education:
Elementary school in Vienna,
High School at the Bundesrealgymnasium GRG 13, Wenzgasse ,
1130 Vienna
High School Graduation in June 1988

College Education:
Medical studies at the University of Vienna,
Graduation as Dr. med. univ. on the 6th July, 1995

Professional Career:
1.11.1995-31.7.1996 research assistant
(Group: Univ. Prof. Dr. R. Prager, Univ.Prof. Dr. B. Ludvik) at the III. Medical Clinic of the University of Vienna

Oct.-Dec. 1996 Diplom of Tropical Medicine

March1997- Oct.1997: Ambulatorium Menosan

Aug. 1997-2002: outpatient department of Endocrinology, Private Clinic Josefstadt (clinical studies on diabetes and obesity)

1.5.1998-30.4.2004: Assistant at Wilheminenspital, V.Dept of Internal Medicine (Prim. Univ.Doz Dr A. Dunky.)

1.5.04: Specialist in Internal Medicine

1.5.2004-1.12.2005: III. Department of Internal Medicine, Department of Endocrinology, Diabetology and Nephrology, Hospital Lainz

Since 2006 own outpatient Department for Internal Medicine, Millergasse 7, 1060 Vienna with a centre for clinical trails.

Professionals Activities abroad:
January 1997, Postgraduate Course on Tropical Medicine, Mahidol University,Bangkok, Thailand

Clinical studies:

trail indication responsibility
HOE 901 (Lantus) Diabetes mellitus type 1 Co-Investigator
HOE 901 (Lantus) Diabetes mellitus type 2 Co-Investigator
Troglitazone Diabetes mellitus type 2 Co-Investigator
ADOPT (Rosiglitazone) Diabetes mellitus type 2 Co-Investigator
Insulin Mixture 25 Diabetes mellitus type 1 Co-Investigator (Phase 1-Studie)
NovoMix 30 Diabetes mellitus type 2 Co-Investigator
Starlix Diabetes mellitus type 2 Co-Investigator
Simvastatin (Zocord) Hyperlipidemia Co-Investigator
Orlistat Obesity Co-Investigator
Ecopipam Obesity Co-Investigator
Topiramate Obesity Co-Investigator
Inhalatives Insulin (Exubera) Diabetes mellitus type 2 Co-Investigator
Liraglutide Diabetes mellitus type 2 Co-Investigator
C1-Rezeptor-Antagonist Obesity Co-Investigator
Bari-2D Diabetes mellitus + CHD Principal Investigator/Diabetology
PRADO (Rimonabant) Obesity Principal Investigator
GETGOAL-X Diabetes mellitus type 2 Principal Investigator
GETGOAL-P Diabetes mellitus type 2 Principal Investigator
DDP-V-Inh+Met Diabetes mellitus type 2 Co-Investigator


Abstracts:

  • Hanusch U.,J.Woodworth, P.Roach, S.Ristic Postprandial and Preprandial Administration of Humalog Mix 25 provide comparable glycemic control.Diabetologia 1999;4 (suppl ):A240
    Printed on the physian portion of  website of „Lilly company“
  • Hanusch-Enserer U., Woodworth J., Roach P., Ristic S. Postprandiale und präprandiale Gabe von Humalog Mix 25 gewährleistet eine vergleichbare Blutzucker-Kontrolle.
    Acta Medica Austriaca 1999;50(26), 9
  • Hanusch-Enserer U, Spak M, Enserer C,Cauza E, Dunky A, Rosen HR, Tüchler H Positive und negative metabolische Veränderungen nach 1Jahr Lap-Band.
    Acta Chir Austriaca 2000 Vol 32 (suppl 162)
  • Enserer C,Hanusch-Enserer U, Spak M, Cauza E, Dunky A,Rosen HR. Laparoskopisches Gastric-Banding nach 105 Patienten.
    Acta Chir Austriaca 2000 Vol 32 (suppl 162)
  • Hanusch-Enserer U., Spak M., Tura A., Cauza E., Dunky A., Wagner O., Pacini G, Rosen H., Prager R. Insulin sensitivity and endothelial dysfunction in morbid obesity  before and 6months after Gastric-Banding.
    Poster ADA 2001
  • Hanusch-Enserer U., Spak M., Cauza E., Dunky A., Tura A., Wagner O., Rosen HR., Pacini G., Prager R. Impact of weight loss after Gastric-Banding on Endothelial dysfunction and insulin sensitivity in morbid obesity. Int J Obes 2001 May Vol25 (supp 2)
    oral presentation ECO 2001
  • Hanusch-Enserer U, Spak M, Cauza E, Dunky A, Rosen HR, Wolf H, Prager R, Eibl M. Akut-Phase Proteine, Leukozytenzahl und Lymphozytensubsets vor und nach massiver Gewichtsreduktion durch Gastric-Banding.
    (oral presentation ÖAG 11/01)
  • Hanusch-Enserer U, Spak M, Cauza E, Dunky A, Wagner O, Rosen HR,Prager R. Ist die endotheliale Dysfunction nach 6 Monaten adjustierbaren gastric-banding positiv beeinflußbar?
    (oral presentation ÖAG 11/01)
  • Hanusch-Enserer U, Spak M, Tura A, Cauza E, Dunky A, Wagner O, Rosen HR, Pacinni G, Prager R. Veränderungen der Insulinsensitivität nach 6 Monaten adjustierbaren Gastric-Banding.
    oral presentation ÖAG 11/01
  • Hanusch-Enserer U., Cauza E., Spak M, Tura A, Dunky A, Wagner O, Pacini G., Rosen HR, Prager R. Einfluß von Gastric-Banding auf Insulinsensitivität und endotheliale Dysfunction in morbid adipösen Patienten.
    Acta Med Austriaca 2001 Vol
  • Hanusch-Enserer U, Spak M, Cauza E, Dunky A, Rosen HR, Wolf H, Prager R, Eibl M. Akut-Phase Proteine, Leukozytenzahl und Lymphozytensubsets vor und nach massiver Gewichtsreduktion durch Gastric-Banding.
    ÖDG 2001
  • Etemad M, Hanusch-Enserer U, Cauza K, Dunky A, Cauza E. HFE genotype in patients with rheumatic disease.
    Ann Rheum Dis 2001 Jul;60 (suppl 1):SAT0190
  • Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatric arthritis and psoriasis vulgaris with the tumor necrosis factor blocker Inflixixmab.
    Ann Rheum Dis 2001 Jul;60 (suppl 1):SAT0014
  • Spak M, Cauza E, Hanusch-Enserer U, Haberhauer G, Dunky A. Clinical results of an open labeled evaluation of the treatment of with Infliximab in therapy resistant rheumatoid arthritis.
    Ann Rheum Dis 2001Jul;60(suppl1):THU0181
  • Cauza E., Hanusch-Enserer U, Strasser B, Georg P, Ludvik B, Spak M,Etemad M, Prager R, Dunky A, Haber P. The effect of resistance training on cardiovascular risk factors in type 2 diabetes patients.
    JACC 2002;39(9)suppl   P53-54
  • Cauza E, Hanusch-Enserer U, Strasser B, Georg P, Ludvik B, Spak M, Etemad M, Dunky A, Haber P. The effect of resistance training on cardiovascular risk factors in type 2 diabetes patients.
    Poster ADA 2002
  • Cauza E, Hanusch-Enserer U, Spak M, Etemad M, Kostner K, Teich G, Dunky A, Ferenci P. Screening for hematochromatosis in Gestational Diabetes.
    Poster ADA 2002
  • Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR. Erfahrungen mit Gastric-Banding bei Patienten mit einem BMI von 50 kg/m² im Rahmen einer multidiziplinären Zusammenarbeit.
    oral presentation, OCG 2002
  • Hanusch-Enserer U, Cauza E, Spak M, Tura A, Dunky A, Wagner O, Pacini G,Rosen HR, Prager R. Adhäsionsmoleküle und Gerinnungsmarker vor und nach Gastric-Banding
    Poster ÖCG 2002
  • Lomoschitz K, Pärtan G, Rosen HR, Hanusch-Enserer U, Schiessel R, Hruby W. 5 Jahre Gastric Banding im Donauspital aus radiologischer Sicht.
    ÖCG 2002
  • Hanusch-Enserer U. Patientenevaluierung aus Sicht des Stoffwechselspezialisten. oral presentation, ÖCG 2002
  • Hanusch-Enserer U. Nachsorgestandard nach Adipositaschirurgie.
    oral presentation, ÖCG 2002
    2xEASD 2002
  • Hanusch-Enserer U., Hermann K.M, Cauza E., Spak M., Mähr B., Dunky A.,Rosen H.R., Prager R., Köller U. Aminoterinmal Pro-Brain natriuretisches Peptid in morbider Adipositas und der  Effekt einer massiven Gewichtsreduktion durch das adjustierbare laparaskopische Gastric-Banding.
    oral presentation, ÖAG 2002
  • E. Cauza, U. Hanusch-Enserer, B. Strasser, B. Ludvik, G. Pacini, O. Wagner, P.Georg, R. Prager,  A. Dunky, P.  Haber P. Der Einfluss von Krafttraining bei Patienten mit Diabetes mellitus Typ 2.
    oral presentation, ÖDG 2002
  • E. Cauza, U. Hanusch-Enserer, B. Strasser, A. Dunky, P. Haber. Der Einfluss von Langzeittraining bei Patienten mit Diabetes mellitus Typ 2.
    oral presentation, ÖDG 2002
  • Hanusch-Enserer U, Cauza E, Brabant G, Rosen HR, Pacini G, Dunky A, Prager R and Roden M. Plasma ghrelin in morbid obesity before and after weight loss following laparoscopical adjustable gastric banding.
    Int J Obes Relat Met Dis 2003;27(supp1):S50 (P1-032)
  • Hanusch-Enserer U, Cauza E, Dunky A, Tura A, Pacini G, Rosen HR, Brabant G, Prager R and Roden M. Plasma ghrelin concentration is not correlated with insulin resistance but increased after severe weight loss in morbid obesity after laparoscopical gastric banding (LAGB).
    Poster,IDF 2003
  • Hanusch-Enserer U, Cauza E, Dunky A, Rosen HR, Giovanni P, Prager R und Roden M. Der Einfluß von Ghrelin auf die Gewichtsabnahme mit Gastric-Banding und auf die Insulinresistenz.
    Acta Medica Austriaca 2003;30, suppl 62:3
  • E. Cauza, U. Hanusch-Enserer, K.Frischmuth, B.Fabian, A.Dunky, K.Kostner. Short-Term Infliximab Therapy Improves Symptoms of Psoriatic Arthritis and Decreases Concentrations of Cartilage Oligomeric Matrix Protein.
    Ann Rheum Dis 2003, Suppl 62; 465
  • Cauza Edmund, Spak Marita, Cauza Karla, Hanusch-Enserer Ursula, Dunky Attila, Wagner Ernst Treatment of Psoriatic Arthritis and Psoriasis vulgaris with the Tumor Necrosis Factor Inhibitor Infliximab.
    J Miner Stoffwechs 2003; 4 :30
  • Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K . Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    J Miner Stoffwechs 2003; 4 :29
  • Edmund Cauza, Ursula Hanusch-Enserer, Mehrdad Etemad, Marcus Köller, Karam Kostner., Petra Georg, Attila Dunky., Peter Ferenci. HFE Genotype in Patients with Rheumatic Diseases
    J Miner Stoffwechs 2003; 4 :30
  • Cauza Edmund, Hanusch-Enserer Ursula, Frischmuth Katrin, Fabian Barbara, Dunky Attila, Kostner Karam. Kurzzeit Therapie mit Infliximab verbessert die Symptome der Psoriasis Arthritis und vermindert die Konzentration vom Cartilage Oligomeric Matrix Protein.
    J Miner Stoffwechs 2003; 4 :30
  • Cauza Edmund, Mehrdad Etemad, Winkler Franz, Hanusch-Enserer U, Partsch Gerald , Noske Helge, Dunky Attila. Pamidronate increases bone mineral density in women with postmenopausal or steroids-induced osteoporosis.
    J Miner Stoffwechs 2003; 4 :30
  • U. Hanusch-Enserer, E. Cauza, M.A. Ghatei, H, G. BRABANT, A. Dunky²R. PrageR, S.R. Bloom, and M. Roden Die Bedeutung der gastrointestinalen Hormone Ghrelin und Peptide YY in Patienten mit ausgeprägten metabolischen Syndrom mit und ohne Diabetes mellitus 2.
    Acta Medica Austriaca 2004; Vol 31: Supplement 64
  • Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P. Kontinuierliche Blutzuckermessungen bei Diabetiker während eines Langstreckenlaufes.
    Acta Medica Austriaca 2004;Vol 31, Supplement 64
  • Klampfl T, Hanusch-Enserer U, Gössinger N, Sokol G, Bachmann A, Hartl D, Walter H, Lesch O. Diabetes mellitus – Depression und Alkoholmissbrauch-Epidemiologie in einer Ordination für Innere Medizin mit Schwerpunkt Diabetes mellitus.
    ÖDG 2006 WikliWo 2006;118:9 (supp)
  • Stadler M, Theuer E, Anderwald C, Karer T, Hanusch-Enserer U, Bieglmayer C, Auinger M, Kästenbauer T, Prager R. Endotheliale Dysfunktion und erhöhte Pulswellengeschwindigkeit bei Typ1 Diabetikern nach kombinierter Nieren-Pankreatransplantation.
    WikliWo 2006;118:20 (supp)
  • Gössinger N, Hanusch-Enserer U, Kästenbauer T, Klampfl T, regal H, Sokol G. Orthopädische Schuhversorgung beim diabetischen Fußsyndrom. Ein Erfahrungsbericht aus der Praxis.
    ÖDG 2006 WikliWo 2006;118:8 (supp)


Publikationen

  • Hanusch-Enserer U., Dunky A. UKPDS und die Konsequenzen auf die Therapie des Diabetes mellitus Typ 2.
    Arzt und Praxis 1999;814: 430-437.
  • Haberhauer G., Feyertag J., Hanusch-Enserer U., Dunky A. Joint hypermobility syndrome and bilateral total occlusion of the ulnar arteries presenting as raynaud`s phenomenon.
    Clin Exp Rheumatol 2000;18(2):270-1
  • Hanusch-Enserer U, Enserer C, Rosen HR, Dunky A. Aktuelle Therapie der morbiden Adipositas.
    Arzt und Praxis 2002
  • Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding.
    Int J Obes 2003;27:355-361
  • Cauza E., Spak M., Cauza K., Hanusch-Enserer U., Haberhauer G., Winkler F., Dunky A., Wagner E. Treatment of psoriatric arthritis and psoriasis vulgaris with the tumor necrosis factor blocker Infliximab
    Rheumatol Int 2002;22(6):227-32
  • Cauza E., Cauza K., Hanusch-Enserer U., Etemad M., Dunky A., Kostner K. Intravenous Anti TNF-alpha antibody therapy leads to an atherogenic plasma lipoprotein profile. Wien Klin Wochenschr 2002;114(23-24):1004-7
  • Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM The effect of severe weight loss after laparoscopic adjustable gastric banding on plasma levels of aminoterminal pro-brain natriuretic peptide (NT- proBNP) in morbidly obese subjects.
    Obes Res 2003;11:695-8
  • Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding.
    N Engl J Med 2003;348:2159-60
  • Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R. Improvement of the Insulin Resistance Syndrome and early endothelial dysfunction in morbidly obese patients following 12 months gastric banding.
    Obes Res 2004:12(2):284-91
  • Ursula Hanusch-Enserer, Edmund Cauza, Georg Brabant, Attila Dunky, Harald Rosen, Giovanni Pacini, Heinz Tuchler, Rudolf Prager, and Michael Roden Plasma Ghrelin in Obesity before and after Weight Loss after Laparoscopical Adjustable Gastric Banding
    J Clin Endocrinol Metab 2004;89 3352-3358
  • Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
    J Clin Pharm Ther. 2004 Oct;29(5):431-6.
  • Hermann KM, Hanusch-Enserer U, Kästenbauer T, Publig T, Dunky A, Rosen HR, Prager R, Köller U. Nt-proBNP as an indicator of possible cardiovascular disease in severely obese: Comparison with patients in different NYHA stages and healthy controls
    Clin Chem 2005;51:138-143
  • Hanusch-Enserer U, Enserer C, Rosen HR, Prager R. Indikationen für die chirurgische Adipositastherapie [Indication for bariatric surgery].
    Acta Medica Austriaca 2004;31(4):125-9
  • Cauza E, Hanusch-Enserer U, Etemad M, Koller M, Kostner K, Georg P, Dunky A, Ferenci P. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis.
    Clin Exp Rheumatol 2005;23(1):7-12
  • Engl J, Hanusch-Enserer U, Prager R, Partsch J,Ebenbichler CF. The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery.
    Wien Klin Wochenschr. 2005;117:243-54.
  • Hanusch-Enserer U, Roden M. News in gut-brain communication: a role of peptide YY (PYY) in human obesity and following bariatric surgery?
    Eur J CIin Invest 2005;35:425-30
  • Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P. The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus.
    Arch Phys Med Rehabil 2005;86:1527-33
  • Cauza E, Hanusch-Enserer U, Bischof M, Spak M, Kostner K, Tamaa A, Dunky A, Ferenci P. Increased C282Y Heterozygosity in Gestational Diabetes.
    Fetal Diagn Ther. 2005;20:349-54.
  • Cauza, E.; Hanusch-Enserer, U.; Strasser, B.; Ludvik, B.; Kostner, K.; Dunky, A.; Haber, P.: Continous glucose monitoring in diabetic long distance runners.
    Int J of Sports Med 2005;26:774-80
  • Cauza, E.; Hanusch-Enserer, U.;Strasser B.; Kostner K.; Dunky A. Haber P.; Strength and endurance training lead to different post exercise glucose profiles in diabetic patients using a continuous subcutaneous glucose monitoring system.
    Eur J Clin Invest 2005;35:745-51
  • Cauza E., Hanusch-Enserer U., Etemad M., Kostner K., Krützmacher H., Dunky A., Ferenci P. Testing for HFE genotype in Austrian patients with diabetes type 2.
    Clin Exp Rheumatol 2005;23:7-12.
  • Kautzky-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U, Prager R., Pacini G. Insulin sensitivity during OGTT and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinediones.
    Diabetes Obes Metab. 2006;8:561-7.
  • Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P. The metabolic effects of long term exercise in Type 2 Diabetes patients.
    Wien Med Wochenschr. 2006;156:515-519.
  • Mark A. Hlatky MD, Kathryn A. Melsop MS, Derek B. Boothroyd PhD and Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators.Ancillary Studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and Opportunities.
    The American Journal of Cardiology 2006; 12: 53-58.
  • Hanusch-Enserer U, MA. Ghatei, E.Cauza, SR. Bloom, R. Prager,M. Roden. Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery.
    Wien Klin Wochenschr. 2007;119:291-6.
  • Basline characteristics of patients with diabetes and coronary disease enrolled in the Bypass Angioplasty revascularization Investigation 2 Diabetes (BARI 2D) trail. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group.
    Am Heart J. 2008;156:528-536, 536.e1-5.
  • Hanusch-Enserer U, Edmund Cauza, Martina Penka, Thomas Kästenbauer, Wolfgang König, Michael Roden, Rudolf Prager, Kurt Huber. Effect of severe weight loss on non-traditional cardiovascular risk factors in morbidly obese subjects.
  • Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group.
    The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Diabetes Care. 2011 34(2):464-7. Free PMC Article
  • Stadler M, Theuer E, Anderwald C, Hanusch-Enserer U, Auinger M, Bieglmayer C, Quehenberger P, Bischof M, Kästenbauer T, Wolzt M, Wagner O, Prager R.
    Persistent arterial stiffness and endothelial dysfunction following successful pancreas-kidney transplantation in Type 1 diabetes.
    Diabet Med. 2009 26(10):1010-8.
  • BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE.
    N Engl J Med. 2009 11;360(24):2503-15.
    A randomized trial of therapies for type 2 diabetes and coronary artery disease.
    PMID: 19502645 [PubMed - indexed for MEDLINE] Free PMC Article
  • Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K.
    Non-conventional markers of atherosclerosis before and after gastric banding surgery.
    Eur Heart J. 2009 30(12):1516-24.
    PMID: 19380349 [PubMed - indexed for MEDLINE] Free Article
  • Cauza E, Strehblow C, Metz-Schimmerl S, Strasser B, Hanusch-Enserer U, Kostner K, Dunstan D, Fasching P, Haber P.
    Effects of progressive strength training on muscle mass in type 2 diabetes mellitus patients determined by computed tomography.
    Wien Med Wochenschr. 2009;159(5-6):141-7.
  • Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators.
    Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
    J Peripher Nerv Syst. 2009 14(1):1-13.


scroll up
scroll down